SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+5.38%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$650M
AUM Growth
+$650M
(+17%)
Cap. Flow
+$97.7M
Cap. Flow
% of AUM
15.02%
Top 10 Holdings %
Top 10 Hldgs %
57.73%
Holding
90
New
18
Increased
17
Reduced
23
Closed
25
Top Buys
| 1 |
Neuropace
NPCE
|
$32.9M |
| 2 |
CRISPR Therapeutics
CRSP
|
$16.7M |
| 3 |
EDAP
EDAP TMS
EDAP
|
$16.5M |
| 4 |
NovoCure
NVCR
|
$16.3M |
| 5 |
C4 Therapeutics
CCCC
|
$15.4M |
Top Sells
| 1 |
BioAtla
BCAB
|
$16.3M |
| 2 |
Xenon Pharmaceuticals
XENE
|
$8.83M |
| 3 |
Krystal Biotech
KRYS
|
$6.75M |
| 4 |
Galecto
GLTO
|
$4.93M |
| 5 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
$4.68M |
Sector Composition
| 1 | Healthcare | 90.8% |
| 2 | Consumer Staples | 2.41% |
| 3 | Financials | 0.49% |
| 4 | Real Estate | 0.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
BioAtla
BCAB
$26.7M
| $118M | 18.21% | 2,794,233 -385,129 | -12% | -$16.3M |
|
2
ESSA Pharma
EPIX
$11.4M
| $63.9M | 9.83% | 2,238,104 +168,052 | +8% | +$4.8M |
|
|
3
C4 Therapeutics
CCCC
$185M
| $32.9M | 5.07% | 870,758 +406,690 | +88% | +$15.4M |
|
|
4
Neuropace
NPCE
$303M
| $32.9M | 5.06% | +1,384,387 | New | +$32.9M |
|
|
THER
5
DELISTED
THERATECHNOLOGIES INC COM
THER
| $27.3M | 4.19% | 7,028,096 +76,749 | +1% | +$298K |
|
6
Lantheus
LNTH
$3.73B
| $25.3M | 3.88% | 913,697 -53,675 | -6% | -$1.48M |
|
|
7
NovoCure
NVCR
$1.38B
| $22M | 3.38% | 98,975 +73,650 | +291% | +$16.3M |
|
|
EDAP
8
EDAP TMS
EDAP
$84.5M
| $18.3M | 2.81% | 2,576,401 +2,326,835 | +932% | +$16.5M |
|
|
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $17.7M | 2.73% | 2,808,343 -572,636 | -17% | -$3.61M |
|
|
10
CRISPR Therapeutics
CRSP
$4.71B
| $16.7M | 2.57% | +103,114 | New | +$16.7M |
|
11
NeoGenomics
NEO
$1.13B
| $15.9M | 2.45% | 352,007 +306,056 | +666% | +$13.8M |
|
12
The Beauty Health Co
SKIN
$264M
| $15.7M | 2.41% | 934,316 +13,600 | +1% | +$228K |
|
13
Surmodics
SRDX
$487M
| $15.1M | 2.32% | 278,404 +124,129 | +80% | +$6.73M |
|
14
AstraZeneca
AZN
$248B
| $15M | 2.3% | 250,146 -8,300 | -3% | -$497K |
|
15
iRadimed
IRMD
$921M
| $14.6M | 2.25% | 497,179 +15,109 | +3% | +$444K |
|
|
ITMR
16
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
| $12.5M | 1.92% | 530,839 +260,759 | +97% | +$6.14M |
|
17
CVRx
CVRX
$205M
| $11.9M | 1.84% | +426,394 | New | +$11.9M |
|
|
SIEN
18
DELISTED
Sientra, Inc.
SIEN
| $11.6M | 1.79% | 1,461,563 +1,083,663 | +287% | +$8.63M |
|
19
Natera
NTRA
$23.1B
| $11.6M | 1.78% | 101,839 +23,600 | +30% | +$2.68M |
|
20
Werewolf Therapeutics
HOWL
$59.9M
| $9.83M | 1.51% | +563,396 | New | +$9.83M |
|
21
Vaxcyte
PCVX
$4B
| $8.46M | 1.3% | 375,650 +82,000 | +28% | +$1.85M |
|
22
Evolus
EOLS
$494M
| $7.34M | 1.13% | +580,000 | New | +$7.34M |
|
|
INBX
23
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $6.68M | 1.03% | 242,789 -158,704 | -40% | -$4.37M |
|
24
Editas Medicine
EDIT
$231M
| $5.42M | 0.83% | +95,600 | New | +$5.42M |
|
|
CUTR
25
DELISTED
Cutera, Inc.
CUTR
| $5.05M | 0.78% | 102,980 -17,020 | -14% | -$834K |
|